Nevertheless, to date, intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative approach for AML and MDS patients with TP53 aberrations [39,40]. This evidence concerns the gene TP53 and myelodysplastic syndrome.